Prognostic Evaluation Based on Dual-Time F-FDG PET/CT Radiomics Features in Patients with Locally Advanced Pancreatic Cancer Treated by Stereotactic Body Radiation Therapy

Overview

Journal J Oncol

Specialty Oncology

Date 2022 Jul 25

PMID 35874634

Authors

Fei Wang

Chao Cheng

Shengnan Ren

Zhongyi Wu

Tao Wang

Xiaodong Yang

Changjing Zuo

Zhuangzhi Yan

Zhaobang Liu

Affiliations

Soon will be listed here.

Abstract

Background: F-FDG PET/CT is widely used in the prognosis evaluation of tumor patients. The radiomics features can provide additional information for clinical prognostic assessment.

Purpose: Purpose is to explore the prognostic value of radiomics features from dual-time F-FDG PET/CT images for locally advanced pancreatic cancer (LAPC) patients treated with stereotactic body radiation therapy (SBRT).

Materials And Methods: This retrospective study included 70 LAPC patients who received early and delayed F-FDG PET/CT scans before SBRT treatment. A total of 1188 quantitative imaging features were extracted from dual-time PET/CT images. To avoid overfitting, the univariate analysis and elastic net were used to obtain a sparse set of image features that were applied to develop a radiomics score (Rad-score). Then, the Harrell consistency index (C-index) was used to evaluate the prognosis model.

Results: The Rad-score from dual-time images contains six features, including intensity histogram, morphological, and texture features. In the validation cohort, the univariate analysis showed that the Rad-score was the independent prognostic factor ( < 0.001, hazard ratio [HR]: 3.2). And in the multivariate analysis, the Rad-score was the only prognostic factor ( < 0.01, HR: 4.1) that was significantly associated with the overall survival (OS) of patients. In addition, according to cross-validation, the C-index of the prognosis model based on the Rad-score from dual-time images is better than the early and delayed images (0.720 vs. 0.683 vs. 0.583).

Conclusion: The Rad-score based on dual-time F-FDG PET/CT images is a promising noninvasive method with better prognostic value.

Citing Articles

Currently Debated Topics on Surgical Treatment of Pancreatic Ductal Adenocarcinoma: A Narrative Review on Surgical Treatment of Borderline Resectable, Locally Advanced, and Synchronous or Metachronous Oligometastatic Tumor.

Pedrazzoli S J Clin Med. 2023; 12(20).

PMID: 37892599 PMC: 10607532. DOI: 10.3390/jcm12206461.

Prognostic Evaluation Based on Dual-Time F-FDG PET/CT Radiomics Features in Patients with Locally Advanced Pancreatic Cancer Treated by Stereotactic Body Radiation Therapy.

Wang F, Cheng C, Ren S, Wu Z, Wang T, Yang X J Oncol. 2022; 2022:6528865.

PMID: 35874634 PMC: 9303166. DOI: 10.1155/2022/6528865.

References

Nakamoto Y, Higashi T, Sakahara H, Tamaki N, Kogire M, Doi R . Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas. Cancer. 2001; 89(12):2547-54. DOI: 10.1002/1097-0142(20001215)89:12<2547::aid-cncr5>3.0.co;2-v. View

Bang S, Chung H, Park S, Chung J, Yun M, Lee J . The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J Clin Gastroenterol. 2006; 40(10):923-9. DOI: 10.1097/01.mcg.0000225672.68852.05. View

Tegos T, Mavrophoros D, Sabetai M, Elatrozy T, Dhanjil S, Karapataki M . Types of neurovascular symptoms and carotid plaque ultrasonic textural characteristics. J Ultrasound Med. 2001; 20(2):113-21; quiz 123. DOI: 10.7863/jum.2001.20.2.113. View

Santhosh S, Mittal B, Bhasin D, Rana S, Bhattacharya A, Srinivasan R . Dual-phase 18F-FDG PET/CT imaging in the characterization of pancreatic lesions: does it offer prognostic information?. Nucl Med Commun. 2014; 35(10):1018-25. DOI: 10.1097/MNM.0000000000000157. View

Mathur A, Hernandez J, Shaheen F, Shroff M, Dahal S, Morton C . Preoperative computed tomography measurements of pancreatic steatosis and visceral fat: prognostic markers for dissemination and lethality of pancreatic adenocarcinoma. HPB (Oxford). 2011; 13(6):404-10. PMC: 3103097. DOI: 10.1111/j.1477-2574.2011.00304.x. View

Hatt M, Majdoub M, Vallieres M, Tixier F, Rest C, Groheux D . 18F-FDG PET uptake characterization through texture analysis: investigating the complementary nature of heterogeneity and functional tumor volume in a multi-cancer site patient cohort. J Nucl Med. 2014; 56(1):38-44. DOI: 10.2967/jnumed.114.144055. View

Aerts H, Velazquez E, Leijenaar R, Parmar C, Grossmann P, Carvalho S . Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach. Nat Commun. 2014; 5:4006. PMC: 4059926. DOI: 10.1038/ncomms5006. View

Zhang A, Ren S, Yuan Y, Li X, Zhu X, Jiang L . Prognostic values of 18F-FDG PET/CT metabolic parameters and clinical figures in locally advanced pancreatic cancer underwent chemotherapy combined with stereotactic body radiation therapy. Medicine (Baltimore). 2019; 98(13):e15064. PMC: 6455984. DOI: 10.1097/MD.0000000000015064. View

Bray F, Ferlay J, Soerjomataram I, Siegel R, Torre L, Jemal A . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68(6):394-424. DOI: 10.3322/caac.21492. View

10.

Juweid M, Cheson B . Positron-emission tomography and assessment of cancer therapy. N Engl J Med. 2006; 354(5):496-507. DOI: 10.1056/NEJMra050276. View

11.

Petrelli F, Comito T, Ghidini A, Torri V, Scorsetti M, Barni S . Stereotactic Body Radiation Therapy for Locally Advanced Pancreatic Cancer: A Systematic Review and Pooled Analysis of 19 Trials. Int J Radiat Oncol Biol Phys. 2017; 97(2):313-322. DOI: 10.1016/j.ijrobp.2016.10.030. View

12.

Tibshirani R . The lasso method for variable selection in the Cox model. Stat Med. 1997; 16(4):385-95. DOI: 10.1002/(sici)1097-0258(19970228)16:4<385::aid-sim380>3.0.co;2-3. View

13.

Lambin P, Leijenaar R, Deist T, Peerlings J, de Jong E, van Timmeren J . Radiomics: the bridge between medical imaging and personalized medicine. Nat Rev Clin Oncol. 2017; 14(12):749-762. DOI: 10.1038/nrclinonc.2017.141. View

14.

Chicklore S, Goh V, Siddique M, Roy A, Marsden P, Cook G . Quantifying tumour heterogeneity in 18F-FDG PET/CT imaging by texture analysis. Eur J Nucl Med Mol Imaging. 2012; 40(1):133-40. DOI: 10.1007/s00259-012-2247-0. View

15.

Kubota K, Matsuzawa T, Ito M, Ito K, Fujiwara T, Abe Y . Lung tumor imaging by positron emission tomography using C-11 L-methionine. J Nucl Med. 1985; 26(1):37-42. View

16.

Chen S, Harmon S, Perk T, Li X, Chen M, Li Y . Diagnostic classification of solitary pulmonary nodules using dual time F-FDG PET/CT image texture features in granuloma-endemic regions. Sci Rep. 2017; 7(1):9370. PMC: 5571049. DOI: 10.1038/s41598-017-08764-7. View

17.

Wang F, Cheng C, Ren S, Wu Z, Wang T, Yang X . Prognostic Evaluation Based on Dual-Time F-FDG PET/CT Radiomics Features in Patients with Locally Advanced Pancreatic Cancer Treated by Stereotactic Body Radiation Therapy. J Oncol. 2022; 2022:6528865. PMC: 9303166. DOI: 10.1155/2022/6528865. View

18.

Lyshchik A, Higashi T, Nakamoto Y, Fujimoto K, Doi R, Imamura M . Dual-phase 18F-fluoro-2-deoxy-D-glucose positron emission tomography as a prognostic parameter in patients with pancreatic cancer. Eur J Nucl Med Mol Imaging. 2004; 32(4):389-97. DOI: 10.1007/s00259-004-1656-0. View

19.

Dholakia A, Chaudhry M, Leal J, Chang D, Raman S, Hacker-Prietz A . Baseline metabolic tumor volume and total lesion glycolysis are associated with survival outcomes in patients with locally advanced pancreatic cancer receiving stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2014; 89(3):539-46. PMC: 4372085. DOI: 10.1016/j.ijrobp.2014.02.031. View

20.

Parghane R, Basu S . Dual-time point F-FDG-PET and PET/CT for Differentiating Benign From Malignant Musculoskeletal Lesions: Opportunities and Limitations. Semin Nucl Med. 2017; 47(4):373-391. DOI: 10.1053/j.semnuclmed.2017.02.009. View